Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the signaling
molecules needed for cell growth. Monoclonal antibodies, such as alemtuzumab, can bind to and
kill malignant lymphocytes.
PURPOSE: This phase I/II trial is studying the side effects and best dose of everolimus when
given together with alemtuzumab and will see how well they work in treating patients with
recurrent chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL).